To Örebro University

oru.seÖrebro University Publications
EnglishSvenskaNorsk
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Strategies to manage hepatitis C virus (HCV) disease burden
Dept Gastroenterol Hepatol & Endocrinol, Hannover Med Sch, Hannover, Germany; German Liver Fdn, Hannover, Germany.
Örebro University, School of Medicine, Örebro University, Sweden. Örebro University Hospital. Dept Infect Dis, Örebro University Hospital, Örebro, Sweden.ORCID iD: 0000-0001-7248-0910
CIBERehd, Hosp Valle De Hebron, Barcelona, Spain.
Div Med, UCL Inst Liver & Digest Hlth, University College, London, London, England.
Show others and affiliations
2014 (English)In: Journal of Viral Hepatitis, ISSN 1352-0504, E-ISSN 1365-2893, Vol. 21, p. 60-89Article in journal (Refereed) Published
Abstract [en]

The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
Place, publisher, year, edition, pages
Hoboken: Wiley-Blackwell, 2014. Vol. 21, p. 60-89
Keywords [en]
Diagnosis, epidemiology, HCV, mortality, treatment, scenarios, prevalence, incidence, hepatitis C, disease burden
National Category
Medical and Health Sciences Infectious Medicine
Research subject
Medicine
Identifiers
URN: urn:nbn:se:oru:diva-34996DOI: 10.1111/jvh.12249ISI: 000333893200004PubMedID: 24713006Scopus ID: 2-s2.0-84902129061OAI: oai:DiVA.org:oru-34996DiVA, id: diva2:716367
Note

Funding Agency:

Gilead Sciences 

Available from: 2014-05-09 Created: 2014-05-09 Last updated: 2020-12-01Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Duberg, Ann-Sofi

Search in DiVA

By author/editor
Duberg, Ann-Sofi
By organisation
School of Medicine, Örebro University, SwedenÖrebro University Hospital
In the same journal
Journal of Viral Hepatitis
Medical and Health SciencesInfectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 647 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
v. 2.46.0
|
WCAG
|
Örebro University Library
|
DiVA Portal
|
DiVA Log in
|
Register in DiVA
|
Contact us